Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review

BackgroundAlpha-thalassemia X-linked intellectual disability (ATR-X) syndrome, is a rare genetic disorder, caused by mutations in the ATRX gene. Clinical manifestations include typical facial dysmorphisms, mild-to-severe intellectual disability, hypotonia, genital anomalies, significant gastrointest...

Full description

Saved in:
Bibliographic Details
Main Authors: F. F. Comisi, C. Soddu, M. Corpino, M. Marica, R. Cacace, T. Foiadelli, S. Savasta
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Pediatrics
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2024.1460658/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850063450865139712
author F. F. Comisi
C. Soddu
M. Corpino
M. Marica
R. Cacace
T. Foiadelli
S. Savasta
author_facet F. F. Comisi
C. Soddu
M. Corpino
M. Marica
R. Cacace
T. Foiadelli
S. Savasta
author_sort F. F. Comisi
collection DOAJ
description BackgroundAlpha-thalassemia X-linked intellectual disability (ATR-X) syndrome, is a rare genetic disorder, caused by mutations in the ATRX gene. Clinical manifestations include typical facial dysmorphisms, mild-to-severe intellectual disability, hypotonia, genital anomalies, significant gastrointestinal (GI) complications, such as abdominal distension, chronic constipation, feeding difficulties, gastroesophageal reflux, and mild-to-moderate anemia secondary to alpha-thalassemia.Case presentationWe report a patient with ATR-X syndrome suffering from gastrointestinal dysmotility and highlight the beneficial effects of pyridostigmine. Knowledge about the role and appropriate dosage of pyridostigmine in GI motility disorders is limited. To date, only nine pediatric cases involving pyridostigmine for GI dysmotility have been reported.ConclusionsConsidering current understanding about the treatment of gastrointestinal complications in patients with genetic syndromes, this case provides new insights into management of these complex clinical presentations.
format Article
id doaj-art-897ec7adda6e435aa0e532485900f2aa
institution DOAJ
issn 2296-2360
language English
publishDate 2024-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pediatrics
spelling doaj-art-897ec7adda6e435aa0e532485900f2aa2025-08-20T02:49:36ZengFrontiers Media S.A.Frontiers in Pediatrics2296-23602024-12-011210.3389/fped.2024.14606581460658Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature reviewF. F. Comisi0C. Soddu1M. Corpino2M. Marica3R. Cacace4T. Foiadelli5S. Savasta6Pediatric Clinic and Rare Diseases, Microcitemico Hospital “A. Cao”, University of Cagliari, Cagliari, ItalyPediatric Clinic and Rare Diseases, Microcitemico Hospital “A. Cao”, Cagliari, ItalyPediatric Clinic and Rare Diseases, Microcitemico Hospital “A. Cao”, Cagliari, ItalyPediatric Clinic and Rare Diseases, Microcitemico Hospital “A. Cao”, Cagliari, ItalyPediatric Clinic and Rare Diseases, Microcitemico Hospital “A. Cao”, University of Cagliari, Cagliari, ItalyPediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyPediatric Clinic and Rare Diseases, Microcitemico Hospital “A. Cao”, University of Cagliari, Cagliari, ItalyBackgroundAlpha-thalassemia X-linked intellectual disability (ATR-X) syndrome, is a rare genetic disorder, caused by mutations in the ATRX gene. Clinical manifestations include typical facial dysmorphisms, mild-to-severe intellectual disability, hypotonia, genital anomalies, significant gastrointestinal (GI) complications, such as abdominal distension, chronic constipation, feeding difficulties, gastroesophageal reflux, and mild-to-moderate anemia secondary to alpha-thalassemia.Case presentationWe report a patient with ATR-X syndrome suffering from gastrointestinal dysmotility and highlight the beneficial effects of pyridostigmine. Knowledge about the role and appropriate dosage of pyridostigmine in GI motility disorders is limited. To date, only nine pediatric cases involving pyridostigmine for GI dysmotility have been reported.ConclusionsConsidering current understanding about the treatment of gastrointestinal complications in patients with genetic syndromes, this case provides new insights into management of these complex clinical presentations.https://www.frontiersin.org/articles/10.3389/fped.2024.1460658/fullgastrointestinal dysmotilityalpha thalassemiaalpha-thalassemia X-linked intellectual disabilityATR-X syndromepyridostigmineconstipation
spellingShingle F. F. Comisi
C. Soddu
M. Corpino
M. Marica
R. Cacace
T. Foiadelli
S. Savasta
Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review
Frontiers in Pediatrics
gastrointestinal dysmotility
alpha thalassemia
alpha-thalassemia X-linked intellectual disability
ATR-X syndrome
pyridostigmine
constipation
title Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review
title_full Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review
title_fullStr Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review
title_full_unstemmed Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review
title_short Pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in ATR-X syndrome. Case report and literature review
title_sort pyridostigmine as a therapeutic option for pediatric gastrointestinal dysmotilities in atr x syndrome case report and literature review
topic gastrointestinal dysmotility
alpha thalassemia
alpha-thalassemia X-linked intellectual disability
ATR-X syndrome
pyridostigmine
constipation
url https://www.frontiersin.org/articles/10.3389/fped.2024.1460658/full
work_keys_str_mv AT ffcomisi pyridostigmineasatherapeuticoptionforpediatricgastrointestinaldysmotilitiesinatrxsyndromecasereportandliteraturereview
AT csoddu pyridostigmineasatherapeuticoptionforpediatricgastrointestinaldysmotilitiesinatrxsyndromecasereportandliteraturereview
AT mcorpino pyridostigmineasatherapeuticoptionforpediatricgastrointestinaldysmotilitiesinatrxsyndromecasereportandliteraturereview
AT mmarica pyridostigmineasatherapeuticoptionforpediatricgastrointestinaldysmotilitiesinatrxsyndromecasereportandliteraturereview
AT rcacace pyridostigmineasatherapeuticoptionforpediatricgastrointestinaldysmotilitiesinatrxsyndromecasereportandliteraturereview
AT tfoiadelli pyridostigmineasatherapeuticoptionforpediatricgastrointestinaldysmotilitiesinatrxsyndromecasereportandliteraturereview
AT ssavasta pyridostigmineasatherapeuticoptionforpediatricgastrointestinaldysmotilitiesinatrxsyndromecasereportandliteraturereview